8-K: Integrated BioPharma Reports Q3 2026 Financial Loss

Integrated BioPharma, Inc. reported a net loss of $0.8 million for the quarter ended March 31, 2026, driven by a 27.3% decline in quarterly revenue.

Summary

• Total revenue for the quarter ended March 31, 2026, was $10.1 million, down 27.3% from $13.9 million in the prior-year period.
• Operating loss for the quarter was $1.1 million, compared to an operating income of $0.7 million in the same quarter of 2025.
• Net loss for the quarter was $0.8 million, or $(0.03) per share, compared to net income of $0.6 million, or $0.02 per share, in the prior-year period.
• Nine-month revenue totaled $34.1 million, a 15.2% decrease from $40.2 million in the same period last year.
• Nine-month net loss was $1.5 million, compared to net income of $1.0 million for the nine months ended March 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to the sharp decline in revenue, the swing to a net loss, and the extreme customer concentration risk.

Positives

• Maintained consistent selling and administrative expenses, which were $0.8 million for the quarter, nearly identical to the $0.8 million reported in the prior-year period.

Negatives

• Significant revenue decline of 27.3% for the quarter and 15.2% for the nine-month period.
• Shift from operating income to operating loss in both the three-month and nine-month periods.
• Gross profit turned into a gross loss of $0.3 million for the quarter ended March 31, 2026.
• High customer concentration, with two largest customers accounting for 90% of total revenue in the nine months ended March 31, 2026.

Risks

• High dependency on two major customers for 90% of total revenue.
• Intense competition and potential loss of market share.
• Pressure on pricing from competitors and purchasers.
• Regulatory changes in the nutraceutical and pharmaceutical manufacturing industries.
• Inflationary pressures, including potential tariffs and tightened labor markets.
• Potential loss of significant customers or suppliers.

Future Outlook

The company did not provide specific quantitative guidance but highlighted risks including economic conditions, competition, regulatory obstacles, and the ability to expand its customer base.

Management Comments

• Our revenue decreased by approximately 15% in the nine-month period ended March 31, 2026 from the nine-month period ended March 31, 2025.
• Revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 90% and 83% of total revenue in the nine months ended March 31, 2026 and 2025, respectively.

Industry Context

StockSavvy.ai notes that Integrated BioPharma faces significant headwinds common in the contract manufacturing space, specifically the high customer concentration risk which leaves the company vulnerable to the procurement decisions of a very small number of clients.

Comparison to Industry Standards

• The company's reliance on two customers for 90% of revenue is significantly higher than the industry standard for diversified contract manufacturers.
• The transition from profitability to operating loss in a high-inflation environment suggests the company is struggling to pass on increased costs to its limited customer base compared to larger, more diversified peers.

Stakeholder Impact

• Shareholders face dilution risk or reduced value due to the swing to net losses.
• Customers may face supply chain uncertainty if the company's financial health continues to deteriorate.
• Employees may face potential restructuring if the company attempts to reduce operating costs to offset losses.

Next Steps

• Continue monitoring the impact of customer concentration on future revenue.
• Observe potential strategic shifts to diversify the customer base.

Key Dates

Recommendation

The combination of a significant revenue drop, a swing to net loss, and extreme customer concentration (90% from two clients) presents a high-risk profile that outweighs current growth prospects.

Keywords

Integrated BioPharma, INBP, nutraceuticals, contract manufacturing, vitamins, financial results, supplements